drug
MOXIFLOXACIN HYDROCHLORIDE
Marketedupdated 3mo agoby Alvogen Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4all catalysts(1)
Trials studying MOXIFLOXACIN HYDROCHLORIDE
- phase1A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD.
- phase1Effects of HSK3486 on Cardiac Repolarization in Health Subjects (TQT)
- phase3PRO-232 in Patients Subjected to Cataract Surgery
- phase4A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
- phase1Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects
- —Effectiveness and Safety of 0.5% Moxifloxacin Hydrochloride Ophthalmic Solution in Perioperative Sterilization in Patients Undergoing Ophthalmic Surgery
- phase1Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 29, 2029
~2.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- May 29, 2029formulationUS 84503112.8y
- May 29, 2029formulationUS 91141682.8y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that